CoChat

Anti‐tumour necrosis factor treatment of inflammatory bowel disease in liver transplant recipients

Mohabbat, A. B., Sandborn, W. J., Loftus, E. V., Wiesner, R. H., Bruining, D. H. · 2012 · Alimentary Pharmacology & Therapeutics
Cited by 61

The DOI matches its Crossref record.

Abstract

Summary: Background: Ulcerative colitis (UC) and C rohn's disease can sometimes relapse and be refractory to standard treatment following orthotopic liver transplantation (OLT) despite post‐transplantation immunosuppressive therapy. Aim: To evaluate the efficacy and safety of anti‐tumour necrosis factor (anti‐TNF) agents for the management of IBD following OLT. Methods: We reviewed the records of patients with a diagnosis of IBD who underwent OLT at M ayo C linic R ochester between 1985 and 2009. Patients were included if they had received anti‐TNF therapy post‐OLT. Clinical response was defined as a physician's assessment of improvement after 12 weeks of anti‐TNF usage, and mucosal healing was defined as the absence of ulcerations on follow‐up endoscopy. Results: The median age of the eight study patients was 42.0 years and 37.5% were female patients. All had been diagnosed with IBD prior to OLT (UC in three and C rohn's disease in five). Indication for OLT was cirrhotic stage primary sclerosing cholangitis (PSC), and three concomitantly had cholangiocarcinoma. Clinical response was demonstrated in seven of eight patients (87.5%) and mucosal healing was demonstrated in three of seven (42.9%). Four infections (oral candidiasis, C lostridium difficile colitis, bacterial pneumonia and cryptosporidiosis) in three patients were reported. One patient developed an E pstein–B arr virus‐positive post‐transplant lympho‐proliferative disorder. One death occurred due to complications from recurrent PSC. Conclusions: Starting Anti‐TNF therapy following orthotopic liver transplantation appears to be a potential option for inflammatory bowel disease management. Additional studies are needed, however, to confirm these findings and to further assess risks associated with this treatment strategy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1365-2036.2012.05217.x

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 61

Metadata

Authors
Mohabbat, A. B., Sandborn, W. J., Loftus, E. V., Wiesner, R. H., & Bruining, D. H.
Venue
Alimentary Pharmacology & Therapeutics
Publisher
Wiley
Published
2012-07-10
Volume
36
Issue
6
Pages
569-574
ISSN
  • 0269-2813 (ISSN-L)
  • 1365-2036
OpenAlex
W2154997623
Cited by
61
References
0
FWCI
2.30
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Anti‐tumour necrosis factor treatment of inflammatory bowel disease in liver transplant recipients. https://app.cochat.ai/papers/10.1111/j.1365-2036.2012.05217.x
The paper
Mohabbat, A. B., Sandborn, W. J., Loftus, E. V., Wiesner, R. H., & Bruining, D. H. (2012). Anti‐tumour necrosis factor treatment of inflammatory bowel disease in liver transplant recipients. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/j.1365-2036.2012.05217.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.